Molbio Subsidiary Secures EU MDR for Imaging Portfolio

Molbio Subsidiary Secures EU MDR for Imaging Portfolio

Prognosys Medical Systems, a subsidiary of Molbio Diagnostics, recently achieved EU MDR certification for its medical imaging portfolio. This milestone signifies a major leap for Indian medical technology. Specifically, the certification from TÜV SÜD allows the company to enter globally regulated markets. Consequently, doctors can trust these digital radiology solutions for high safety and clinical performance standards, often utilized by professionals who have completed a Certification Course In Clinical Imaging.

Impact of EU MDR Certification on Global Diagnostics

The ProRad portfolio now aligns with the rigorous standards of Regulation (EU) 2017/745. Because this regulation emphasizes patient safety and clinical evidence, the certification validates the quality of Indian-made imaging tools. Furthermore, Molbio aims to combine molecular diagnostics with radiological imaging. This integration supports faster disease detection in decentralized healthcare settings. Therefore, the achievement strengthens the ‘Make in India’ initiative on a global stage, bridging the gap in diagnostics for those training in specialized radiological practices.

Advancing Radiology with Integrated Solutions

Integrated diagnostics represent the future of efficient medical care. By pairing radiology with molecular testing, healthcare providers can diagnose conditions more accurately. Moreover, Prognosys offers both fixed and mobile platforms to improve diagnostic access. These mobile systems are particularly useful in remote areas where infrastructure is limited. Thus, the new certification ensures these life-saving tools meet the world’s most stringent regulatory requirements, supporting the work of clinicians who have pursued advanced radiology certifications to improve patient outcomes.

Frequently Asked Questions

Q1: What is the significance of EU MDR certification for imaging devices?

The certification indicates that the imaging devices meet the highest European standards for safety, quality, and clinical performance. It is essential for manufacturers who want to market their products in the European Union and other globally regulated regions.

Q2: How does the ProRad portfolio support decentralized healthcare?

The ProRad range includes mobile digital radiology platforms designed for use in diverse settings. These systems enable faster diagnosis at the point of care, which is vital for improving patient outcomes in remote or underserved areas.

References

1. Molbio Diagnostics digital radiology arm secures EU MDR certification forimaging portfolio – ETHealthworld
2. European Union Medical Device Regulation (EU MDR) 2017/745 Guidelines
3. Official Website of Prognosys Medical Systems

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.